I was having lunch with a colleague when the conversation turned to a deal we had been following from the outside. A well-regarded animal health company had been acquired, and the CEO, someone who had built the business over the better part of a decade, had agreed to stay on through the transition. I remember thinking what I have thought many times watching founder-led and family-run companies in this industry get acquired: they often do not fully understand what they are signing up for.
In the weeks after that acquisition closed, the leadership team was quietly dismantled. The VP of Regulatory Affairs was gone. The head of formulation science who had guided three products through approval was gone. The senior commercial director who had spent a decade earning the trust of distributors across multiple regions was gone. Not because these people had failed in any measurable way, but because the acquiring company had its own structure and intended to use it. The CEO watched it happen from the inside and could not stop it.
Then the second wave came. The instability of those departures sent a signal through the organization, and competing firms read it clearly. Recruiters started calling. Within months, some of the most experienced R&D scientists in the business had been quietly recruited away by competitors who understood exactly what that disruption had made available. That business spent more than four years trying to recover, four years of stalled pipeline, weakened client relationships, and depressed output on what had been a genuinely strong operation.
Then there is a second story, shorter and in some ways even harder to argue with. A smaller animal health business was acquired by a large corporation. The products were the same. The systems were the same. The team was largely intact. The one exception was the main salesperson, the person who had been the face of that company to its customers for years. That person was not retained. Within two years, the business was shut down.
One person. Two years. Gone.
I share both stories not as warnings from some distant industry but as a window into what happens in animal health when an acquirer pays for the assets and walks away from the engine.
The Framework I Have Carried Since the Classroom
In trying to make sense of a pattern I kept seeing in front of me, I took a disruptive innovation course under Clayton Christensen, a professor at Harvard Business School whose thinking on organizational failure and value destruction became one of the most influential frameworks in modern business. It changed the way I look at mergers and acquisitions entirely. When I watch a consolidator absorb a founder-led animal health company and immediately begin standardizing what made it distinctive, I think about what he taught. When I see the best people leave in the first ninety days and the acquirer express surprise at what follows, I think about what he taught.
In a 2011 Harvard Business Review article co-authored with Richard Alton, Curtis Rising, and Andrew Waldeck, Christensen put a number to what most deal teams already sense but rarely confront directly: companies invest more than two trillion dollars in acquisitions every year, and yet study after study puts the failure rate somewhere between 70% and 90%. His explanation for why was precise. Most acquirers pay for resources, things like intellectual property, regulatory approvals, product lines, and customer contracts, and then inadvertently dismantle the processes and values that made those resources generate returns.
Resources are visible and transferable. You can assign a dollar figure to a patent or a distribution agreement. Processes are different. They live in how decisions get made, how a clinical submission gets built, how a field team earns and keeps trust over years of repeated interaction. Values are what the organization actually protects when no one is watching. In a family-run animal health business, those values are often held by a small number of people, and when those people are gone, the values go with them.
The CEO in the first story lost his regulatory lead, his formulation head, and his commercial director in the weeks after close. What the acquirer saw were line items on a headcount spreadsheet. What walked out the door was the process architecture behind three pipeline products, a decade of regulatory credibility, and the personal relationships holding the distributor network together. The second story makes the same point with less room for debate. Remove the one person who owned the customer relationships, and the business does not survive.
Christensen and his colleagues argued that so many acquisitions fall short not because the math was wrong, but because acquirers incorrectly match their integration approach to the strategic purpose of the deal. They absorb businesses that should be preserved. They standardize what should remain differentiated. And they do it all at speed, under pressure from finance teams optimizing synergy timelines.
| What Was Purchased | What Was Lost | Business Impact |
| VP of Regulatory Affairs | Institutional knowledge of approval pathways, agency relationships | Pipeline slippage, compliance risk |
| Head of Formulation Science | Proprietary technical expertise, R&D continuity | Stalled product development, competitor poaching opportunity |
| Commercial Director | Distributor trust, regional network, tacit customer knowledge | Revenue attrition, relationship breakdown |
| Key Salesperson | Customer relationships, brand trust, revenue continuity | Business closure within two years |
Why Animal Health Is Particularly Exposed
Animal health is not a transactional industry. It is a relationship industry that happens to have transactions in it.
A salesperson who has spent years calling on the same Veterinary practices, the same distributors, the same key opinion leaders does not transfer those relationships to the acquiring company by signing a contract or, as in the second story, by simply not being there at all. That network is personal and conditional. It was built on years of showing up consistently, following through reliably, and understanding what each customer actually needed from the relationship. When that person is gone, the CRM system still has the contact names. It does not have the trust.
This is precisely what competing firms understand in the months following an acquisition. The instability, or in some cases the sudden quiet, creates a recruiting window. In animal health, where a single experienced regulatory scientist or well-connected commercial leader can meaningfully accelerate a competitor’s trajectory, those departures are not just retention losses. They are competitive wealth transfers. The acquiring company paid a premium for capability that is now working against it.
This dynamic is particularly acute in the family-run and founder-led businesses that make up many of the animal health companies changing hands right now. These organizations often hold what makes them work well in relationships rather than systems, in judgment rather than policy, and in the personal credibility of a small number of people rather than in a brand that transfers by legal agreement.
The Negotiation Conversation That Belongs in the Term Sheet
Both sides of the table in animal health tend to treat integration as a post-close problem. It is not. It is a negotiation topic, and it belongs in the deal structure itself.
For buyers, the most important shift is moving retention provisions beyond aggregate headcount targets. Revenue metrics can be met even as the business hollows out beneath the surface. What actually protects value is naming specific individuals in clinical, regulatory, and commercial leadership within the deal terms, with earnout provisions tied directly to their continued presence and the continuity of the customer relationships they carry. If the business depends on one salesperson, that person’s retention is not an HR detail. It is a deal condition.
For sellers, the leverage here is significant and routinely left on the table. A founder who has spent years building a differentiated animal health company has standing to negotiate for a defined period of operational autonomy before standardization begins, for governance provisions that protect core clinical protocols from immediate override, and for joint decision-making on key personnel in the period after close. Nuno Fernandes, whose research on M&A value destruction was published through the Harvard Law School Forum on Corporate Governance, argues that talent exodus is a significant and avoidable risk in most acquisitions, and that senior management must be prepared to answer the question of what happens to key people before those people are forced to ask it themselves. In animal health, where that question goes unanswered, competitors answer it instead.
The questions that actually predict post-close performance are rarely on the standard diligence checklist. Who are the two or three people without whom this business is materially different, and what is the plan to retain them before close rather than after? How does the commercial team interact with its customers, and is that interaction replicable without those specific individuals? What informal decision-making structures exist that will not survive a standard org chart redesign? What does this culture actively protect, and what would feel like a violation to the people who built it? These are not soft questions. They are valuation questions, and the answers belong in the term sheet.
What Good Integration Actually Looks Like
The acquirers that consistently create value in animal health are not the ones who move fastest. They are the ones who understand a fundamental tension that researchers Julia Bodner and Laurence Capron identified in their 2018 study published in the Journal of Organization Design: every integration involves a genuine trade-off between coordination and autonomy. Impose too much coordination too quickly and you destroy the operating architecture that generated the returns you paid for. Preserve too much autonomy indefinitely and you never capture the synergies that justified the price. Getting that balance right requires being deliberate about sequence, not just speed.
Birkinshaw, Bresman, and Håkanson, in their research on post-acquisition integration published in the Journal of Management Studies, found that the acquisitions that create value follow a specific order. Human integration, meaning the development of trust, cultural understanding, and mutual respect between the two organizations, must proceed alongside and ultimately precede deeper task integration, meaning the full alignment of systems, processes, and reporting structures. In the deals that fail, that sequence is inverted. Systems get integrated first because they are visible and reportable to a board. People and culture get managed last. And by the time the acquirer notices what is eroding, the window to retain the people who mattered has already closed.